LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Reduces Price of Weight-Loss Drug Zepbound Amidst Competitive Pressure
Eli Lilly announced on December 1, 2025, that it is lowering the cash price for starting doses of its popular weight-loss drug, Zepbound, when purchased...
🔴 LLY is trading 3.01% down today after major shareholder sells $178.42 million in shares
LLY is trading at 3.01% down now at $1,071.06 following a $178.42 million share sale by Lilly Endowment Inc on November 25, which reduced the endowment's...
Eli Lilly Establishes South Korean Production Hub for Blockbuster Obesity Drug Mounjaro
Eli Lilly is set to establish a production base in South Korea for its highly successful GLP-1 obesity treatment, Mounjaro. This marks the first time a GLP-1...
🟢 LLY is trading 3.1% up today after Bernstein raised its price target and ongoing GLP-1 drug momentum
LLY is trading at 3.1% up now at $1103.38 after Bernstein raised its price target to $1,300 from $1,100 on November 25, 2025, citing stronger catalysts ahead...
Billionaire Investor Stanley Druckenmiller Sells Entire Eli Lilly Stake
Billionaire investor Stanley Druckenmiller's fund sold its entire position in Eli Lilly during the third quarter, as revealed in the latest filings. The move...
Lilly and Novo Nordisk to Offer Zepbound and Wegovy Directly to Companies
Eli Lilly and competitor Novo Nordisk will begin offering their popular weight-loss drugs, Zepbound and Wegovy, directly to companies starting January 1, 2025....
Eli Lilly's Oral Obesity Drug Orforglipron Shows Positive Results in Diabetes Patients
Eli Lilly announced study results for its oral obesity treatment, orforglipron, demonstrating its effectiveness in adults with both obesity and type 2...
Eli Lilly Surges Past $1,000 Amid Stock Split Speculation
On November 19, 2025, Eli Lilly (LLY) closed at $1049.60 (+1.90%), continuing its rapid ascent above the $1,000 mark. This surge is fueled by the ongoing...
Eli Lilly Approaches $1 Trillion Market Cap as Zepbound Drives Growth
On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, helping...
Eli Lilly Nears $1 Trillion Valuation as Zepbound Drives Optimism
On November 18, 2025, major financial media reported that Eli Lilly's weight-loss drug Zepbound is on track to become the world's top-selling drug, fueling...
JPMorgan Raises Eli Lilly Price Target to $1,150 Citing Obesity Drug Strength
JPMorgan has increased its price target for Eli Lilly to $1,150 from $1,050, reiterating an Overweight rating on the stock. The investment bank's optimism is...
Eli Lilly Receives Approval for Alzheimer's Drug Donanemab in India, JPMorgan Raises Price Target
Eli Lilly has received marketing authorization from India's Central Drugs Standard Control Organization for donanemab, its treatment for early symptomatic...
Eli Lilly Announces $2.6 Billion Multi-Program Collaboration with ABL Bio
On November 18, 2025, Eli Lilly announced a $2.6 billion multi-program collaboration agreement with ABL Bio to develop therapeutics using ABL Bio’s Grabody...
Eli Lilly Receives Approval for Alzheimer's Drug Donanemab in India
Eli Lilly and Company has received marketing authorization from India's Central Drugs Standard Control Organization (CDSCO) for its Alzheimer's treatment,...
JPMorgan Raises Eli Lilly Price Target to $1150 on Strong Obesity Drug Outlook
JPMorgan has increased its price target for Eli Lilly stock to $1,150 from $1,050, while reiterating an "Overweight" rating. The updated forecast came after...
JP Morgan Raises Eli Lilly Price Target to $1150 Amid Strong Drug Portfolio Momentum
On November 18, 2025, JP Morgan raised its price target for Eli Lilly (LLY) to $1150, reflecting increased confidence in the company's growth prospects and...
Eli Lilly's Alzheimer's Drug Donanemab Gains Approval in India
Eli Lilly and Company announced it has received marketing authorization for its Alzheimer's drug, donanemab, from India's Central Drugs Standard Control...
LLY Drops After Novo Nordisk Slashes Obesity Drug Prices
On November 17, 2025, Eli Lilly (LLY) shares declined after Novo Nordisk announced significant price reductions for its weight-loss drugs Wegovy and Ozempic,...
Eli Lilly Strikes $2.6 Billion Licensing Deal with ABL Bio for Antibody Technology
Eli Lilly and Company has entered into a significant licensing and joint research agreement with South Korean biotech firm ABL Bio for its bispecific antibody...
Eli Lilly's Blockbuster Drugs Single-Handedly Drive Ireland's 2025 GDP Growth by 11%
A report from The Irish Times on November 12, 2025, revealed that Eli Lilly's blockbuster weight-loss drugs, Mounjaro and Zepbound, are the primary drivers...